Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus X TROZINE L A.
PROMETHAZINE DM vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine